- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01706445
Combined Inspiratory Muscle and 'Whole Muscle' Training in Children With Cystic Fibrosis
October 11, 2012 updated by: Alejandro Lucia, Universidad Europea de Madrid
To study the effects of an 8-week combined inspiratory muscle training and exercise (resistance+aerobic) program on of a lung volume, inspiratory muscle strength (maximal inspiratory pressure, PImax) and cardiorespiratory fitness (maximal oxygen uptake, VO2peak) (primary outcomes)and dynamic muscle strength, body composition and quality of life (QoL) in children with Cystic Fibrosis (CF) (secondary outcomes).
Study Overview
Detailed Description
The investigators hypothesized that the combined training program would significantly benefit most of the aforementioned variables (especially, primary outcomes).
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Madrid, Spain
- Hospital Infantil Universitario Nino Jesus
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- boy/girl aged 6-17 years
- living in the Madrid area
Exclusion Criteria:
- severe lung deterioration [forced expiratory volume (FEV1) <50% of expected]
- unstable clinical condition (hospitalization within the previous 3 months)
- Burkholderia cepacia infection
- any disorder (e.g. muscle-skeletal) impairing exercise.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
|
|
Other: intervention
Exercise training
|
inspiratory muscle training (IMT) + aerobic and strength training 8-week duration IMT twice a day (mostly at home) + 3 weekly sessions of inhospital resistance + aerobic training
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cardiorespiratory fitness (VO2peak)
Time Frame: this outcome will be assessed up to 12 weeks
|
maximum oxygen uptake (VO2peak), which is the best indicator of aerobic fitness in humans and an independent mortality predictor in children with cystic fibrosis
|
this outcome will be assessed up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
quality of life
Time Frame: this outcome will be assessed up to 12 weeks
|
children's QoL with the Spanish Version (1.0) of the Cystic Fibrosis Questionnaire-Revised (CFQ-R).
|
this outcome will be assessed up to 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximal inspiratory pressure (PImax)
Time Frame: september 2011-july 2012
|
an indicator of the strength of inspiratory muscles
|
september 2011-july 2012
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Actual)
July 1, 2012
Study Registration Dates
First Submitted
October 9, 2012
First Submitted That Met QC Criteria
October 11, 2012
First Posted (Estimate)
October 15, 2012
Study Record Updates
Last Update Posted (Estimate)
October 15, 2012
Last Update Submitted That Met QC Criteria
October 11, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- kid'strainingCF
- CFtraining (Registry Identifier: PS09/00194)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on Other
-
University of MinnesotaCompleted
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingDecompensated CirrhosisIndia
-
Ruijin HospitalNot yet recruitingLymphoma | DLBCL - Diffuse Large B Cell LymphomaChina
-
Hugo W. Moser Research Institute at Kennedy Krieger...Johns Hopkins UniversityRecruitingADHD | Attention Deficit Hyperactivity DisorderUnited States
-
Cutera Inc.CompletedAcne Scars - Mixed Atrophic and HypertrophicUnited States
-
Capital Medical UniversityQilu Hospital of Shandong University; Beijing Chao Yang Hospital; Qingdao Municipal... and other collaboratorsUnknownCommunity Acquired PneumoniaChina
-
Washington University School of MedicineRecruitingDepression | Coronary Heart DiseaseUnited States
-
Aarogyam UKUniversity of Warwick; NMP Medical Research Institute; Mothers Touch FoundationCompleted
-
AmgenCompletedRelapsed/Refractory Acute Lymphoblastic LeukemiaUnited States
-
University of LeicesterUniversity Hospitals, Leicester; Leicester City Clinical Commissioning Group; West Leicestershire Clinical Commissioning Group and other collaboratorsCompletedCardiovascular Diseases | Chronic Kidney Diseases | Cardiovascular Risk FactorUnited Kingdom